The group has in the past – together with cooperation partners – isolated and analysed several plant constituents for their potential to prevent cardiovascular diseases. Leoligin, the major lignan isolated from the roots of Edelweiss, is currently the most promising agent, and currently intensively analysed by the team.
Leoligin showed an impressive activity in inhibiting bypass graft intimal hyperplasia, increasing the durability of bypass grafts, and Leoligin was shown to beneficially affect the lipid status in humans.
It is estimated that in ~ 2 years the team will start with the first human trials with this compound
The group is further working on compounds for the treatment of myocardial infarction. The goal is to define compounds that stimulate angiogenesis, and protect cardiomyocytes from hypoxia-induced damage.